{"status": "Ok", "redirect_url": "https://www.businesswire.com/news/home/20260529816966/en/Exelixis-Announces-Results-from-Subgroup-Analysis-of-Phase-3-CABINET-Pivotal-Trial-Evaluating-CABOMETYX%C2%AE-cabozantinib-in-Non-Functional-and-Functional-Neuroendocrine-Tumors-at-ASCO-2026", "message": "News view counter 769114 successfully enlarged"}